IPM saw steady growth of 7.2% in Apr/May’25, led by steady 10% growth in the chronic segment, which was partly offset by ~6% growth in the acute segment for the same period.
Pharma coverage will see 11% YoY sales growth, driven by an 11% YoY increase in the India business along with 2% QoQ growth in US sales (+2% YoY). The hospital business is projected to grow by 15% YoY, as muted occupancy will be partly supported by steady average revenue per occupied beds, as well as M&As (Max Healthcare).